Olema Pharmaceuticals (OLMA) Liabilities and Shareholders Equity (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $530.6 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 29.54% year-over-year to $530.6 million in Q1 2026; TTM through Mar 2026 was $1.8 billion, a 33.69% increase from a year earlier, with the FY2025 full-year figure at $533.4 million, up 18.28% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $530.6 million, down from $533.4 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for OLMA reached as high as $533.4 million in Q4 2025 and fell as low as $177.6 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $313.3 million across 5 years, with a median of $276.9 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity decreased 29.43% in 2023 and surged 62.84% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $215.6 million in 2022, then advanced by 28.43% to $276.9 million in 2023, then soared by 62.84% to $451.0 million in 2024, then rose by 18.28% to $533.4 million in 2025, then declined by 0.52% to $530.6 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $530.6 million in Q1 2026, $533.4 million in Q4 2025, and $352.5 million in Q3 2025.